Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Pemetrexed in elderly NSCLC (CJLSG1901)
NCT04396457Phase 2Unknown
- Sponsor
- National Hospital Organization Nagoya Medical Center
- Start
- May 2020
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by National Hospital Organization Nagoya Medical Center. Status: unknown.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04396457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396457.